Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVITA Medical, Inc.RCEL · Entity 5905 | Director · CEO | June 04, 2025 | June 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVITA Medical, Inc.
Report date June 04, 2025 · Filed June 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.73 · Expires 2035-01-21 | Direct | 520,000 |
Reported balance
After 2025-01-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-21 · Grant · Acquired 520,000 · Balance 520,000 F1: On January 7, 2025, the Board of Directors approved a grant of 520,000 options to acquire 520,000 shares of Common Stock of the Company (the "Common Stock") to Mr. Corbett, with an effective grant date of January 21, 2025 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $8.73. This grant was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025. F2: These Stock Options vest in three equal annual installments beginning on the date 12 months following the grant date of January 21, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 7, 2025, the Board of Directors approved a grant of 520,000 options to acquire 520,000 shares of Common Stock of the Company (the "Common Stock") to Mr. Corbett, with an effective grant date of January 21, 2025 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $8.73. This grant was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.
F2: These Stock Options vest in three equal annual installments beginning on the date 12 months following the grant date of January 21, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 21, 2025 Filed Jun 5, 2025 16:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 520,000 | $0.00 Strike: $8.73 | $0.00 |
DisclosureSEC source: 0000950170-25-082389 · ownership.xml · derivative · entry 1 CORBETT JAMES · CIK 0001238620 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 520,000 Underlying: Common Stock · 520,000 shares Expires 2035-01-21 F1 · derivative.exercise_price: On January 7, 2025, the Board of Directors approved a grant of 520,000 options to acquire 520,000 shares of Common Stock of the Company (the "Common Stock") to Mr. Corbett, with an effective grant date of January 21, 2025 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $8.73. This grant was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025. F2 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning on the date 12 months following the grant date of January 21, 2025. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 19:02 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0000950170-24-070082 · ownership.xml · derivative · entry 1 CORBETT JAMES · CIK 0001238620 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2034-01-03 F1 · derivative.exercise_price: Pursuant to Mr. Corbett's Employment Agreement, he is eligible for annual equity grants. On January 3, 2024, the Board of Directors approved a grant of 350,000 options to acquire 350,000 shares of Common Stock of the Company to Mr. Corbett, with an effective grant date of January 3, 2024 and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on January 3, 2024 of $12.64. The grant was subject to the approval of the Company's stockholders, which was obtained on June 5, 2024. F2 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning on the date 12 months following the grant date of January 3, 2024. Read SEC document |
| December 26, 2023 Filed Dec 27, 2023 17:02 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | SaleCommon | 1,445 | $13.29 | $19,204.05 |
DisclosureSEC source: 0000950170-23-073346 · ownership.xml · nonDerivative · entry 1 CORBETT JAMES · CIK 0001238620 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,580 F1 · shares: Shares sold to cover tax obligation incurred by the Reporting Person upon the vesting of RSUs. F1 · price: Shares sold to cover tax obligation incurred by the Reporting Person upon the vesting of RSUs. F2 · balance_after: Includes unvested RSUs Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 16:33 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $14.17 | $0.00 |
DisclosureSEC source: 0001209191-23-035432 · doc4.xml · derivative · entry 1 CORBETT JAMES · CIK 0001238620 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-06-06 F1 · shares: The reporting person may elect to acquire the Issuer's CHESS Depositary Interests ("CDIs") in place of common stock upon exercise of a Stock Option. CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of common stock and have all the rights and privileges of common stock. F2 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning on the date 12 months following the grant date. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 17:23 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 226,296 | $0.00 Strike: $5.64 | $0.00 |
DisclosureSEC source: 0001209191-22-061280 · doc4.xml · derivative · entry 1 CORBETT JAMES · CIK 0001238620 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,296 Underlying: Common Stock · 226,296 shares Expires 2032-09-28 F1 · date: These Stock Options were previously granted pursuant to the Reporting Person's Employment Agreement, dated September 26, 2022 and effective September 28, 2022, subject to stockholder approval. On December 12, 2022, the Issuer's stockholders approved the grant of the Stock Options at the Issuer's annual meeting. F2 · derivative.exercise_date: These Stock Options vest in four equal annual installments beginning on September 28, 2023. Read SEC document |
| December 22, 2021 Filed Dec 27, 2021 16:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 2,550 | $0.00 Strike: $12.18 | $0.00 |
DisclosureSEC source: 0001209191-21-071252 · doc4.xml · derivative · entry 4 CORBETT JAMES · CIK 0001238620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,550 Underlying: Common Stock · 2,550 shares Expires 2031-12-22 F5 · derivative.exercise_date: These Stock Options vest on the date 12 months following the grant date. Read SEC document |
| December 22, 2021 Filed Dec 27, 2021 16:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 4,925 | $0.00 Strike: $12.18 | $0.00 |
DisclosureSEC source: 0001209191-21-071252 · doc4.xml · derivative · entry 3 CORBETT JAMES · CIK 0001238620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,925 Underlying: Common Stock · 4,925 shares Expires 2031-12-22 F4 · derivative.exercise_date: These Stock Options vest in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| December 22, 2021 Filed Dec 27, 2021 16:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 4,350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-071252 · doc4.xml · nonDerivative · entry 2 CORBETT JAMES · CIK 0001238620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,025 F3 · price: Represents an award of RSUs that vest on the date 12 months following the grant date. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| December 22, 2021 Filed Dec 27, 2021 16:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 8,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-071252 · doc4.xml · nonDerivative · entry 1 CORBETT JAMES · CIK 0001238620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,675 F1 · price: Represents an award of Restricted Stock Units ("RSUs"), each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments on the first, second and third anniversaries of the grant date. F2 · balance_after: Includes unvested RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.